biostudies-literatureLee LYWCancer Research UKBlood Cancer UKNational Institute for Health Research (NIHR)188-196https://www.ebi.ac.uk/biostudies/studies/S-EPMC9936347biostudies-literatureUnknown9(2)<h4>Importance</h4>Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer.<h4>Objective</h4>To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer.<h4>Design, setting, and participants</h4>This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagnoJAMA oncologyAssociation of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.PMC9936347ACF-2019-02-0102899030195CL-2018-02-002CL-2018-18-002ACF-2017-19-002CL-2018-11-002ACF-2020-02-006Middleton MClark JFowler TLittle MGhafoor QWilliams STCattell EShah KMiddleton GPanneerselvam HSheehan RTaylor HProtheroe ASKinloch EPatel GLydon AJohal SRozmanowski SHattersley RMurphy GGrumett SPatel VKahn RGerrand KStarkey TIonescu MCPotter VMcKenzie HYing YIveson TBernhardt KRigg ASWilliams SAl-Hajji YLam ETuthill MRhodes MSintler MFittall MWJohnson PBuckley ASwarup SLee AJXRoux RLRoques THarper-Wynne CCheng VBenny LRandle APlatt JREastlake LPascoe JLee SMBeggs ARobinson KTilby MLee LYWTillett TBytyci JAppanna NTripathy AUK COVID Cancer ProgrammeRobinson TWatts IRoylance RBurnett ALiu JKHBarnard MKhan SfalseAssociation of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.<h4>Importance</h4>Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer.<h4>Objective</h4>To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer.<h4>Design, setting, and participants</h4>This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagno2023-01-01T00:00:00Z2023 Feb2025-04-21T15:58:12.078Z2024-11-08T09:16:36.826ZS-EPMC99363473654797010.1001/jamaoncol.2022.5974